Date |
Headline |
Docs |
18 Dec 2017 |
Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer |
|
13 Dec 2017 |
Targovax to present at DNB healthcare conference |
|
11 Dec 2017 |
Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews |
|
30 Nov 2017 |
Targovax ASA: New member of the board of directors |
|
14 Nov 2017 |
Targovax to present at upcoming investor conferences |
|
07 Nov 2017 |
Targovax ASA: Notice of Extraordinary General Meeting |
|
02 Nov 2017 |
Targovax ASA: Third quarter 2017 results |
|
24 Oct 2017 |
Targovax ASA: Invitation to third quarter 2017 results presentation Thursday 2 November |
|
12 Oct 2017 |
Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer |
|
03 Oct 2017 |
Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02 |
|
25 Sep 2017 |
Targovax granted US Patent for mutant-RAS neoantigen platform lead products |
|
14 Sep 2017 |
Targovax Receives 2017 Nordic Stars Award |
|
11 Sep 2017 |
Targovax ASA: Three posters presented at ESMO conference |
|
24 Aug 2017 |
Targovax ASA: Second quarter and first half 2017 results |
|
23 Aug 2017 |
Targovax ASA: Abstracts accepted for poster presentation at the ESMO 2017 Congress |
|
14 Aug 2017 |
Targovax ASA: Invitation to second quarter and first half 2017 results presentation Thursday 24 August |
|
09 Jun 2017 |
Targovax ASA: Notice of Extraordinary General Meeting |
|
09 Jun 2017 |
Targovax ASA - Information on the subsequent offering - Key date information |
|
08 Jun 2017 |
TARGOVAX ASA - SUCCESSFULLY COMPLETED PRIVATE PLACEMENT |
|
06 Jun 2017 |
Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting |
|
06 Jun 2017 |
Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London |
|
18 May 2017 |
Targovax ASA: ASCO abstract released |
|
10 May 2017 |
Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study |
|
08 May 2017 |
Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017 |
|
25 Apr 2017 |
Targovax ASA: First quarter 2017 results |
|
20 Apr 2017 |
Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform |
|
19 Apr 2017 |
Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April |
|
06 Apr 2017 |
Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting |
|
05 Apr 2017 |
Targovax ASA: Protocol from the Annual General Meeting |
|
04 Apr 2017 |
Targovax ASA: Proposal from the nomination committee to the annual general meeting 5 April 2017 |
|
23 Mar 2017 |
Targovax ASA moves share listing to Oslo Børs |
|
15 Mar 2017 |
Targovax ASA: Notice of Annual General Meeting |
|
15 Mar 2017 |
Targovax ASA: Annual Report 2016 |
|
06 Mar 2017 |
Targovax to present at upcoming conferences |
|
16 Feb 2017 |
Targovax ASA: Fourth quarter and full year 2016 results |
|
06 Feb 2017 |
Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February |
|
02 Feb 2017 |
Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients |
|
05 Jan 2017 |
Targovax announces appointment of Erik Digman Wiklund as CFO |
|